[go: up one dir, main page]

AR103666A1 - COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO - Google Patents

COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO

Info

Publication number
AR103666A1
AR103666A1 ARP160100380A ARP160100380A AR103666A1 AR 103666 A1 AR103666 A1 AR 103666A1 AR P160100380 A ARP160100380 A AR P160100380A AR P160100380 A ARP160100380 A AR P160100380A AR 103666 A1 AR103666 A1 AR 103666A1
Authority
AR
Argentina
Prior art keywords
6alkyl
aryl
group
heteroaryl
optionally substituted
Prior art date
Application number
ARP160100380A
Other languages
English (en)
Inventor
Schmidt Wolfgang
Night Chris
Linney Ian
Carzaniga Laura
Rizzi Andrea
Rancati Fabio
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52469670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR103666(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of AR103666A1 publication Critical patent/AR103666A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Compuestos que actúan como antagonistas de los receptores muscarínicos a la vez que como agonistas del receptor b2 adrenérgico, procesos para su preparación, composiciones que los comprenden, usos terapéuticos y combinaciones con otros ingredientes farmacéuticamente activos. Reivindicación 1: Un compuesto caracterizado porque son de fórmula general (1) donde Q es un grupo de fórmula (2); Y se selecciona entre Y² e Y¹ que son grupos divalentes de fórmula (3) ó (4), donde A¹ y A² en forma independiente están ausentes o se seleccionan entre C₁₋₁₂alquileno, C₃₋₈cicloalquileno y C₃₋₈heterocicloalquileno opcionalmente sustituido con uno o más sustituyentes seleccionados entre C₁₋₆alquilo, aril-C₁₋₆alquilo y heteroaril-C₁₋₆alquilo; B se encuentra ausente o se selecciona entre C₃₋₈cicloalquileno, C₃₋₈heterocicloalquileno, arileno o heteroarileno opcionalmente sustituido con uno o más grupos seleccionados entre -OH, halógenos, -CN, C₁₋₆alquilo, C₁₋₆alcoxi, C₁₋₆haloalquilo, C₁₋₆haloalcoxi y aril-C₁₋₆alquilo; C se encuentra ausente o se selecciona entre -O-, -C(O)-, -OC(O)-, -(O)CO-, -S-, -S(O)-, -S(O)₂- y -N(R⁷)-, o es uno de los restos C1 - C23 del grupo de fórmulas (5), donde R⁷ es en cada caso en forma independiente H o se selecciona entre C₁₋₈alquilo lineal o ramificado, aril-C₁₋₆alquilo, arilsulfanilo, arilsulfinilo, arilsulfonilo, C₃₋₈cicloalquilo, C₃₋₈heterocicloalquilo, arilo, y heteroarilo; D se encuentra ausente o se selecciona entre C₁₋₁₂alquileno, C₂₋₁₂alquenileno, C₂₋₆alquinileno, arileno, heteroarileno, C₃₋₈cicloalquileno, C₃₋₈heterocicloalquileno; donde dicho arileno, heteroarileno, C₃₋₈cicloalquileno y C₃₋₈heterocicloalquileno está opcionalmente sustituido con uno o más grupos seleccionados entre -OH, halógeno, -CN, C₁₋₆alquilo, C₁₋₆alcoxi, C₁₋₆haloalquilo, C₁₋₆haloalcoxi y aril-C₁₋₆alquilo; n es en cada caso en forma independiente 0 o un entero entre 1 y 3; m es en cada caso en forma independiente un entero entre 1 y 3; E se encuentra ausente o se selecciona entre -O-, -NR⁷-, -NR⁷-C(O)-, -C(O)-NR⁷-, -OC(O)-, -C(O)-(CH₂)ₙ-O-, -NR⁷-C(O)-(CH₂)ₙ-O-, -NR⁷-C(O)-NR⁷- y -S-; G es arileno o heteroarileno, opcionalmente sustituido con uno o más sustituyentes seleccionados entre átomos de halógeno, -OH, oxo (=O), -SH, -NO₂, -CN, -CON(R⁶)₂, -NH₂, -NHCOR⁶, -CO₂R⁶, C₁₋₁₀alquilsulfanilo, C₁₋₁₀alquilsulfinilo, C₁₋₁₀alquilsulfonilo, C₁₋₁₀alquilo, arilo, haloarilo, heteroarilo y C₁₋₁₀alcoxi; R¹ se selecciona entre C₃₋₈cicloalquilo, C₃₋₈heterocicloalquilo, arilo, heteroarilo, aril-C₁₋₆alquilo, heteroaril-C₁₋₆alquilo y C₃₋₈cicloalquil-C₁₋₆alquilo, opcionalmente sustituido con uno o mas grupos seleccionados en forma independiente entre halógeno, C₁₋₈alquilo, y C₁₋₁₀alcoxi; s es 0 o un entero entre 1 y 3; R² es un grupo que contiene nitrógeno que puede seleccionarse entre: un grupo (a) que es -NR³R⁴ donde R³ y R⁴ son en forma independiente hidrógeno o C₁₋₄alquilo; y un grupo (b) restos de fórmula J1 - J5 seleccionados del grupo de fórmulas (6); R⁵ es un grupo de fórmula (7); donde p es 0 o un entero entre 1 y 4; q es 0 o un entero entre 1 y 4; P se encuentra ausente o se selecciona entre el grupo divalente que consiste en O, S, SO, SO₂, CO, NR⁶CH=CH, N(R⁶)SO₂, N(R⁶)COO, N(R⁶)C(O), SO₂N(R⁶), OC(O)N(R⁶) y C(O)N(R⁶); W se selecciona entre H, C₁₋₆alquilo, C₃₋₈cicloalquilo, arilo y heteroarilo, opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre átomos de halógeno, -OH, oxo (=O), -SH, -NO₂, -CN, -CON(R⁶)₂, -NH₂, -NHCOR⁶, -CO₂R⁶, C₁₋₁₀alquilsulfanilo, C₁₋₁₀alquilsulfinilo, C₁₋₁₀alquilsulfonilo, C₁₋₁₀alquilo y C₁₋₁₀alcoxi; R⁶ es en cada caso en forma independiente H o se selecciona entre C₁₋₁₀alquilo, C₁₋₆haloalquilo, C₂₋₆alquinilo, C₂₋₆alquenilo, C₃₋₈cicloalquilo, heteroarilo y arilo opcionalmente sustituido con uno o más sustituyentes seleccionados entre átomos de halógeno, -OH, oxo (=O), -SH, -NO₂, -CN, -CONH₂, -COOH, C₁₋₁₀alcoxicarbonilo, C₁₋₁₀alquilsulfanilo, C₁₋₁₀alquilsulfinilo, C₁₋₁₀alquilsulfonilo, C₁₋₁₀alquilo y C₁₋₁₀alcoxi; y sales farmacéuticamente aceptables o solvatos del mismo.
ARP160100380A 2015-02-12 2016-02-11 COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO AR103666A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15154917 2015-02-12

Publications (1)

Publication Number Publication Date
AR103666A1 true AR103666A1 (es) 2017-05-24

Family

ID=52469670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100380A AR103666A1 (es) 2015-02-12 2016-02-11 COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO

Country Status (26)

Country Link
US (2) US9579314B2 (es)
EP (1) EP3256464B1 (es)
JP (1) JP6905466B2 (es)
KR (1) KR20170115069A (es)
CN (1) CN107207473B (es)
AR (1) AR103666A1 (es)
AU (1) AU2016217955B2 (es)
BR (1) BR112017017296A2 (es)
CA (1) CA2976150A1 (es)
CL (1) CL2017002017A1 (es)
CO (1) CO2017008031A2 (es)
EA (1) EA032937B9 (es)
ES (1) ES2916924T3 (es)
GE (2) GEP20207098B (es)
IL (1) IL253922B (es)
MA (1) MA41492A (es)
MX (1) MX369348B (es)
PE (1) PE20171347A1 (es)
PH (1) PH12017501424B1 (es)
PL (1) PL3256464T3 (es)
SG (1) SG11201706455QA (es)
TN (1) TN2017000346A1 (es)
TW (1) TWI703138B (es)
UA (1) UA124138C2 (es)
WO (1) WO2016128456A1 (es)
ZA (1) ZA201705376B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018011090A1 (en) * 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
ES2836113T3 (es) 2016-12-14 2021-06-24 Beijing Showby Pharmaceutical Co Ltd Clase de compuestos bifuncionales con estructura de sal de amonio cuaternario
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2019015640A1 (zh) * 2017-07-21 2019-01-24 四川海思科制药有限公司 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途
KR20200067170A (ko) 2017-10-05 2020-06-11 풀크럼 쎄러퓨틱스, 인코포레이티드 FSHD의 치료를 위하여 DUX4 및 하류 유전자 발현을 저감시키는 p38 키나제 저해제
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20200088278A (ko) 2018-01-10 2020-07-22 고꾸리쯔 다이가꾸 호진 오이타 다이가꾸 셀룰로오스 나노화이버 및 그것으로 구성된 시트상 재료, 및 그들의 제조 방법
CA3097083A1 (en) 2018-05-15 2019-11-21 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
BR112023015210A2 (pt) 2021-01-29 2023-11-07 Cedilla Therapeutics Inc Inibidores de cdk2 e métodos de uso dos mesmos
MX2023015436A (es) 2021-06-26 2024-02-21 Cedilla Therapeutics Inc Inhibidores de cdk2 y metodos de uso de los mismos.
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4616264B2 (ja) * 2003-05-28 2011-01-19 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとしてのアザビシクロアルカン化合物
JP4851937B2 (ja) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
FR2898640B1 (fr) 2006-03-20 2008-04-25 Siemens Vdo Automotive Sas Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
CA2679059A1 (en) * 2007-02-28 2008-09-04 Cipla Limited Process for preparing isomers of carmoterol
PL2599778T3 (pl) 2009-04-23 2018-01-31 Theravance Respiratory Co Llc Związki diamidowe mających działanie antagonisty receptora muskarynowego i agonisty receptora adrenergicznego beta 2
WO2011048409A1 (en) * 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP2386555A1 (en) * 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
WO2012168349A1 (en) * 2011-06-10 2012-12-13 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN103562198B (zh) 2011-06-10 2016-08-24 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
SG11201504318UA (en) * 2012-12-06 2015-07-30 Chiesi Farma Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR102156441B1 (ko) * 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물

Also Published As

Publication number Publication date
UA124138C2 (uk) 2021-07-28
TN2017000346A1 (en) 2019-01-16
GEAP201914563A (en) 2019-12-25
CN107207473B (zh) 2020-07-07
KR20170115069A (ko) 2017-10-16
CA2976150A1 (en) 2016-08-18
WO2016128456A1 (en) 2016-08-18
CO2017008031A2 (es) 2017-11-10
TWI703138B (zh) 2020-09-01
ES2916924T3 (es) 2022-07-06
PH12017501424A1 (en) 2018-01-15
JP6905466B2 (ja) 2021-07-21
BR112017017296A2 (en) 2018-04-10
CN107207473A (zh) 2017-09-26
US9579314B2 (en) 2017-02-28
ZA201705376B (en) 2018-12-19
MX2017010366A (es) 2018-01-23
JP2018510137A (ja) 2018-04-12
PE20171347A1 (es) 2017-09-13
AU2016217955A1 (en) 2017-08-31
IL253922A0 (en) 2017-10-31
IL253922B (en) 2019-11-28
TW201636338A (zh) 2016-10-16
PL3256464T3 (pl) 2022-07-18
EA032937B1 (ru) 2019-08-30
EP3256464B1 (en) 2022-05-11
EA201791579A1 (ru) 2018-02-28
SG11201706455QA (en) 2017-09-28
US10004728B2 (en) 2018-06-26
EP3256464A1 (en) 2017-12-20
MX369348B (es) 2019-11-06
US20160235734A1 (en) 2016-08-18
US20170119753A1 (en) 2017-05-04
MA41492A (fr) 2021-04-28
GEP20207098B (en) 2020-04-10
PH12017501424B1 (en) 2018-01-15
CL2017002017A1 (es) 2018-04-13
AU2016217955B2 (en) 2020-03-05
EA032937B9 (ru) 2019-11-27

Similar Documents

Publication Publication Date Title
AR103666A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
AR088023A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR093825A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR093832A1 (es) COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR089333A1 (es) Antagonistas del receptor de vanilloides de potencial transitorio 1 (trpv1)
AR090548A1 (es) Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
MX390698B (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
AR098621A1 (es) Derivados de heteroarilo
AR093795A1 (es) Oxidos de piridinio, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades respiratorias
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
AR105820A1 (es) Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
AR094929A1 (es) Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
AR093798A1 (es) Compuestos
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CO2017000222A2 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR103192A1 (es) Isotiazolamidas, procesos para su preparación y su uso como herbicidas y/o reguladores del crecimiento vegetal
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
PE20160933A1 (es) Antagonista selectivos de nr2b
AR101077A1 (es) Triterpenoides con actividad inhibidora de la maduración de hiv

Legal Events

Date Code Title Description
FG Grant, registration